NKTX Nkarta, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1787400 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-25.7%
TTM EPS YoY-25.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-46.6%
ROA-35.1%
ROIC (approx.)-50.0%
Asset turnover—
Leverage & solvency
Liabilities / assets30.1%
Debt / equity0.00x
Current ratio5.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | — | — | — |
| R&D expense | $90.43M | $96.74M | $96.77M | $90.90M | $63.41M |
| SG&A expense | $31.57M | $31.45M | $34.88M | $28.06M | $23.02M |
| Operating income | -$122.00M | -$128.19M | -$131.65M | -$118.95M | -$86.43M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$104.08M | -$108.79M | -$117.50M | -$113.84M | -$86.08M |
| EBITDA | -$112.80M | -$118.99M | -$125.75M | -$116.36M | -$84.63M |
| EPS (basic) | -1.41 | -1.60 | -2.40 | -2.61 | -2.62 |
| EPS (diluted) | -1.41 | -1.60 | -2.40 | -2.61 | -2.62 |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | — | — |
| Weighted avg. shares (diluted) | 73.99M | 67.87M | 49.01M | 43.63M | 32.86M |
| Balance sheet | |||||
| Cash & equivalents | $39.63M | $27.87M | $31.04M | $37.49M | $60.82M |
| Short-term investments | $236.65M | $239.48M | $217.15M | $314.65M | $177.27M |
| Current assets | $282.51M | $273.34M | $253.07M | $360.69M | $245.78M |
| PP&E, net | $66.72M | $74.66M | $79.33M | $61.91M | $12.86M |
| Total assets | $404.21M | $501.20M | $378.88M | $472.94M | $273.90M |
| Current liabilities | $22.27M | $18.92M | $23.33M | $22.05M | $12.94M |
| Total liabilities | $91.88M | $93.23M | $105.60M | $100.73M | $22.94M |
| Shareholders' equity | $312.32M | $407.98M | $273.29M | $372.21M | $250.97M |
| Shares outstanding | 71.08M | 70.65M | 49.18M | 48.88M | 32.97M |
| Cash flow statement | |||||
| Operating cash flow | -$88.70M | -$99.70M | -$86.16M | -$57.00M | -$67.93M |
| Capital expenditure | $1.21M | $4.41M | $28.15M | $47.11M | $5.03M |
| Free cash flow | -$89.91M | -$104.11M | -$114.31M | -$104.11M | -$72.95M |
| Investing cash flow | $100.32M | -$129.56M | $79.02M | -$184.69M | $32.53M |
| Financing cash flow | $141,000 | $226.08M | $691,000 | $219.01M | $1.20M |
| Depreciation & amortization | $9.20M | $9.20M | $5.90M | $2.60M | $1.80M |
| Stock-based compensation | $8.56M | $16.73M | $17.20M | $16.86M | $14.46M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.